ITGB2 can be used as a potential marker of mesenchymal molecular subtypes of gliomas and as an independent predictive marker of OS in patients with malignant gliomas and provides new insights into the immunotherapy of LGG. Here, ITGB2 is linked to central nervous system cancer.